Loading ...
Strongyloides stercoraliscan causehyperinfection syndrome
Strongyloides stercoraliscan causehyperinfection syndrome
mutations in the LPIN2 gene(passive) is caused byMajeed syndrome
heterozygous missense mutations in the SAM domain of p63(passive) is caused byHay?Wells syndrome
a cystic duct remnant calculuscausingMirizzi syndrome
a deletion on Chromosome 21q11(passive) is caused byCardiovelofacial syndrome
Mycoplasma pneumonia infection in Japan(passive) caused byStevenseJohnson syndrome
filariform larvaecausinghyperinfection syndrome
Were Foundcould resultin combination syndrome
residual thrombuscausingpostphlebitic syndrome
the disease ... the mutated genescauseMajeed Syndrome
although the SMAD4 mutations in JP - HHT patients do show a tendency to cluster in the MH2 domaincausethe combined syndrome
Mutations in the PTEN genecan causeCowden syndrome
by mutations in the PTEN gene(passive) is caused byCowden syndrome
mutations in the PTEN gene(passive) is caused byCowden syndrome
Mutations of the PTEN gene , a tumor suppressor genecauseCowden syndrome
mutation in the PTEN gene(passive) is caused byCowden syndrome
a mutation in the PTEN gene(passive) is caused byCowden syndrome
may fuse to the extrahepatic biliary treecausingMirizzi syndrome
by germline mutations in PTEN(passive) is causedCowden syndrome
by germline mutations in PTEN(passive) is caused byCowden syndrome
a mutation in the PTEN gene , which is normally a tumour suppressor gene(passive) is caused byCowden syndrome
Dr. Mary Claire KingdiscoveredBRCA1 syndrome
These mutations ... mutationscausecardiofaciocutaneous syndrome
mutationscausecardiofaciocutaneous syndrome
by mutations in the PTEN(passive) is ... caused byCowden syndrome
mutations in a gene on chromosome 10 known as PTEN(passive) is caused byCowden syndrome
the PTEN genecauseCowden syndrome
PTEN ) genecausingCowden syndrome
the PTEN genecausesCowden syndrome
mutations in several genes(passive) can be caused byCardiofaciocutaneous syndrome
a mutation in the SMAD4 gene(passive) is caused byMyhre syndrome
mutations in the SMAD4 gene(passive) is caused byMyhre syndrome
Novel SMAD4 mutationcausingMyhre syndrome
by faults in the PTEN gene(passive) caused byCowden syndrome
a single shared homozygous founder mutation in SGOL1 , a component of the cohesin complexcausesCAID syndrome
genecauseCowden syndrome
a novel mutation(passive) caused byCowden syndrome
Inherited mutations On this genemight causeCowden syndrome
Inherited mutations With this genecan causeCowden syndrome
and dyed textile of various cultures worldwidepaintedand dyed textile of various cultures worldwide
vinyl stickers and waterslide decalspaintedvinyl stickers and waterslide decals
to a greater blood pressure reduction and faster blood pressure lowering to target levels , prompter response in a larger number of patients , lower probability of discouraging patient adherence with many treatment changes and reduced risk of hospitalization due to cerebrovascular and coronary events in about 25 %leadsto a greater blood pressure reduction and faster blood pressure lowering to target levels , prompter response in a larger number of patients , lower probability of discouraging patient adherence with many treatment changes and reduced risk of hospitalization due to cerebrovascular and coronary events in about 25 %
in higher Erk1/2 inhibition and in increased induction of apoptosisresultedin higher Erk1/2 inhibition and in increased induction of apoptosis
prominent and durable tumor regression compared to single agent therapycausesprominent and durable tumor regression compared to single agent therapy
in longer and better management of symptomscan resultin longer and better management of symptoms
in a reduction of tumor volume by 78 % ( p < 0.001 ) compared with the control groupresultedin a reduction of tumor volume by 78 % ( p < 0.001 ) compared with the control group
in better symptom control than an increased dosage of ICS alone [ 27may resultin better symptom control than an increased dosage of ICS alone [ 27
in maximum antitumor effects in the second model , where precancerous cells were already presentalso resultedin maximum antitumor effects in the second model , where precancerous cells were already present
to superior outcomesledto superior outcomes
alsoledalso
to more superior outcomemay leadto more superior outcome
in message levels similar to that seen with RAresultedin message levels similar to that seen with RA
reductions in tissue infarction and vascular injurycausesreductions in tissue infarction and vascular injury
tumor regression but was not well tolerated and decreased survival , suggesting that artemisinins should not be used in therapeutic strategiescausedtumor regression but was not well tolerated and decreased survival , suggesting that artemisinins should not be used in therapeutic strategies
of ingredients of plant and synthetic origincomposedof ingredients of plant and synthetic origin
in a > 2-log reduction for rifampin , compared to antimicrobial treatment aloneresultedin a > 2-log reduction for rifampin , compared to antimicrobial treatment alone
in statistically significant enhanced induction of MCL cell deathresultedin statistically significant enhanced induction of MCL cell death
to more significant improvements assigned to applications for drugsledto more significant improvements assigned to applications for drugs
in complete clearance of vessels and diffuse rednessresultedin complete clearance of vessels and diffuse redness
to an average survival of 15 - 17 months ... compared with 10 - 12 months for 5FU treatment aloneleadsto an average survival of 15 - 17 months ... compared with 10 - 12 months for 5FU treatment alone
in significantly higher sustained virological responses ( 53 %resultedin significantly higher sustained virological responses ( 53 %
to decreased Arg1-positivity compared to anti - CTLA-4 aloneledto decreased Arg1-positivity compared to anti - CTLA-4 alone
in no significant differencesresultedin no significant differences
to PUMA induction , acute apoptosis , and autophagyleadingto PUMA induction , acute apoptosis , and autophagy
to any sensitization of cell linesdid ... leadto any sensitization of cell lines
in a significant reduction in the expression of cyclin D1 and c - Mycresultedin a significant reduction in the expression of cyclin D1 and c - Myc
the accumulation of cells at G1 phase with the increases in the sub - G0 / G1 peak , DNA ladder , nuclear fragmentation , and caspase-3/7 activitysignificantly causedthe accumulation of cells at G1 phase with the increases in the sub - G0 / G1 peak , DNA ladder , nuclear fragmentation , and caspase-3/7 activity
rashes and skin reactionsmay causerashes and skin reactions
most significant ( P<0.001 ) reduction in body weight ... fasting blood glucose , serum levels of cholesterol , triglyceride , LDL , VLDL and increase levels of HDLcausedmost significant ( P<0.001 ) reduction in body weight ... fasting blood glucose , serum levels of cholesterol , triglyceride , LDL , VLDL and increase levels of HDL
rashes and skin reactions to sunlightmay causerashes and skin reactions to sunlight
in apoptosis through the formation of tBid , mitochondrial membrane depolarizationresultedin apoptosis through the formation of tBid , mitochondrial membrane depolarization
caspase - dependent apoptosis , PARP cleavage and Annexin Vcausescaspase - dependent apoptosis , PARP cleavage and Annexin V
in broadly effective cell kill of p53 WT and p53-negative cancer cellsresultedin broadly effective cell kill of p53 WT and p53-negative cancer cells
to increased IOP or initiation of antihypertensive eyedrops in 19 ( 29 % ) eyesledto increased IOP or initiation of antihypertensive eyedrops in 19 ( 29 % ) eyes
to a shift from T reg to T eff cells within the tumorleadsto a shift from T reg to T eff cells within the tumor
to greater clinical improvements for children with ADHDcould leadto greater clinical improvements for children with ADHD
in improved inhibition or delay the development of resistance in vitrowould resultin improved inhibition or delay the development of resistance in vitro
in increased clinical benefitmay resultin increased clinical benefit
to faster improvements ( without significantly affecting magnitudeledto faster improvements ( without significantly affecting magnitude